ClearPoint Neuro, Inc. (CLPT) |
| 13.44 -0.4 (-2.89%) 06-12 16:00 |
| Open: | 13.8 |
| High: | 14.12 |
| Low: | 13.07 |
| Volume: | 443,604 |
| Market Cap: | 403(M) |
| PE Ratio: | -13.44 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 17.64 |
| Resistance 1: | 15.10 |
| Pivot price: | 12.88 |
| Support 1: | 12.52 |
| Support 2: | 10.93 |
| 52w High: | 30.1 |
| 52w Low: | 8.27 |
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
| EPS | -1.000 |
| Book Value | 0.630 |
| PEG Ratio | 0.61 |
| Gross Profit | 0.844 |
| Profit Margin (%) | -71.57 |
| Operating Margin (%) | -69.90 |
| Return on Assets (ttm) | -25.0 |
| Return on Equity (ttm) | -149.7 |
Mon, 08 Jun 2026
ClearPoint Neuro (CLPT) director exercises options and withholds shares for taxes - Stock Titan
Tue, 02 Jun 2026
Director at ClearPoint Neuro (NASDAQ: CLPT) sells shares to cover taxes - Stock Titan
Fri, 29 May 2026
[144] ClearPoint Neuro, Inc. SEC Filing - Stock Titan
Tue, 26 May 2026
Director at ClearPoint Neuro (CLPT) receives 12,820 restricted stock units grant - Stock Titan
Tue, 26 May 2026
[Form 4] ClearPoint Neuro, Inc. Insider Trading Activity - Stock Titan
Tue, 26 May 2026
How The ClearPoint Neuro (CLPT) Narrative Is Shifting On Partnerships Valuation And FDA Risks - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |